PLA2G7 and Alzheimer disease: Rilapladib, a hydroquinoline-based small molecule drug developed by GlaxoSmithKline was used as a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor or 1-alkyl-2-acetylglycerophosphocholine esterase inhibitor for treating atherosclerotic plaques and Alzheimer's disease (Shaddinger et al., 2014).